SCHEMBL6152215

SCHEMBL6152215

CCCC[Sn](CCCC)CCCC.Clc1cc2ccccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.43
HDAC3 O15379 1/20 0.41
MAOA P21397 2/20 0.39
SIRT2 Q8IXJ6 2/20 0.39
SIRT1 Q96EB6 2/20 0.39
LMNA P02545 2/20 0.38
KDM4E B2RXH2 3/20 0.38
LOXL2 Q9Y4K0 1/20 0.38
MGLL Q99685 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
AGXT P21549 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6152213 0.81 HDAC3 (0.41) MAOBHDAC3MAOASIRT2SIRT1
SCHEMBL31154576 0.79 KDM4E (0.54) MAOBMAOALMNAKDM4ELOXL2
SCHEMBL686830 0.79 KDM4E (0.54) MAOBMAOALMNAKDM4ELOXL2
Ethoxycarbonyl Group SCHEMBL28518665 0.71 CYP2A6 (0.44) MAOBMAOALMNAKDM4ELOXL2
SCHEMBL1287509 0.68 LOXL2 (0.56) MAOBHDAC3LMNALOXL2L3MBTL1
SCHEMBL29594271 0.68 LOXL2 (0.56) MAOBHDAC3LMNALOXL2L3MBTL1
SCHEMBL17058606 0.68 S1PR1 (0.46) MEN1NPC1KMT2A
SCHEMBL252581 0.67 MAPT (0.60) MAOBHDAC3MAOALOXL2L3MBTL1
Hydrochloric Acid SCHEMBL28989961 0.67 LOXL2 (0.55) MAOBHDAC3LOXL2L3MBTL1SMN1; SMN2
SCHEMBL8688187 0.66 MAPT (0.63) MAOBHDAC3MAOALOXL2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1586638-A1 Monoclonal antibody for immunologically analyzing or concentrating endocrine disruptor or its degradation product and utilization of the same Japan EnviroChemicals, Ltd. (JP) 2005-10-19 EP disclosed
US-20030087324-A1 Monoclonal antibody for immunologically analyzing or concentrating endocrine disruptor or its degradation product and utilization of the same JAPAN ENVIROCHEMICALS, LTD. (JP) 2003-05-08 US disclosed
EP-1057890-A1 MONOCLONAL ANTIBODY FOR IMMUNOLOGICALLY ANALYZING OR CONCENTRATING ENDOCRINE DISRUPTING SUBSTANCE OR ITS DEGRADATION PRODUCT AND UTILIZATION OF THE SAME Takeda Chemical Industries, Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087324-A1 Monoclonal antibody for immunologically analyzing or concentrating endocrine disruptor or its degradation product and utilization of the same SHBG, BCL6, SERPINA6 MAOB 4495/4885HDAC3 3615/4885MAOA 3684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.